LLY

Eli Lilly & Co.

Healthcare Drug Manufacturers - General NYSE

About the company

Eli Lilly and Company, commonly known as Lilly, is a global pharmaceutical company with a rich history of more than 140 years. Founded by Colonel Eli Lilly in 1876, the company has become a leader in the healthcare industry, dedicating its efforts and resources to develop innovative treatments to improve the lives of patients around the world. Lilly's focus on neuroscience underscores its commitment to finding solutions for some of the most complex and challenging diseases affecting the brain and nervous system. Through extensive research, Lilly aims to uncover new therapies to address conditions such as Alzheimer's disease, Parkinson's disease, migraine, depression, and schizophrenia. The company recognizes the immense burden that mental health disorders place on both patients and their families, and thus strives to provide effective treatment options that can enhance cognitive function, alleviate symptoms, and ultimately improve overall quality of life. In the realm of cardiometabolic disorders, Lilly has developed groundbreaking medications to treat conditions such as diabetes and cardiovascular diseases. One of their notable products, Jardiance, has been shown to dramatically reduce the risk of cardiovascular death in patients with type 2 diabetes mellitus. Additionally, Trulicity, a once-weekly injectable medication, has proven to be highly effective in managing blood sugar levels and reducing the risk of major adverse cardiovascular events. These medications exemplify Lilly's commitment to advancing treatments that not only address the symptoms but also target the underlying causes of cardiometabolic disorders. Lilly's dedication to oncology is evident through the development of Verzenio, a targeted therapy for breast cancer. Verzenio has shown promising results in extending survival and improving quality of life for patients battling advanced or metastatic breast cancer. The company is also involved in the exploration of other cancer treatments, with ongoing research and development efforts aimed at identifying innovative therapies for a wide range of malignancies. By collaborating with renowned oncology centers and experts worldwide, Lilly aims to contribute to significant advancements in cancer care. In the field of immunology, Lilly has made significant strides in developing medications for autoimmune diseases. Their product Taltz, for example, is used to treat conditions such as psoriasis, psoriatic arthritis, and ankylosing spondylitis. Taltz targets specific proteins involved in the body's immune response, effectively reducing inflammation and providing relief to patients suffering from these debilitating diseases. Another immunology product, Olumiant, has shown efficacy in the treatment of rheumatoid arthritis by inhibiting the activity of enzymes responsible for promoting inflammation within the joints. With a strong focus on research and development, Lilly continuously seeks to identify unmet medical needs and explore new therapeutic avenues. This commitment can be witnessed through their extensive clinical trials and collaborations with academic institutions, government agencies, and other pharmaceutical companies. By constantly pushing the boundaries of science and technology, Lilly aims to unlock potential breakthroughs in medicine that can revolutionize patient care and contribute to the advancement of global health. Overall, Eli Lilly's dedication to the areas of neuroscience, cardiometabolic disorders, oncology, and immunology demonstrates their steadfast commitment to improving the well-being of individuals worldwide. As a leading pharmaceutical company, Lilly strives to develop innovative treatments that address the most pressing medical challenges of our time. Through their cutting-edge research and collaborative efforts, they continue to make significant contributions to the field of healthcare, ultimately aiming to provide hope and restore health to patients in need.

Website: https://www.lilly.com

Data updated: June 2, 2026

Sector comparison

We compare this company with the typical (middle) company in the same industry to show how it looks against similar businesses. This is information, not a recommendation.

Healthcare · 1346 peers in sector

Metric LLY Sector median Vs. industry
P/E 38.46 20.10 ↑ Above average
EPS 28.14 USD -1.14 USD ↑ Above average
Dividend yield 0.56% 0.00% ↑ Above average
Profit margin 34.99% 0.00% ↑ Above average
ROE 1.07% -58.84% ↑ Above average

Higher and lower here are only a comparison with the typical company in the industry — a higher or lower value on its own does not mean better or worse.

Financial statements & historical data

Income statements, balance sheets, cash flow, earnings and dividend history are available for registered users

Sign up for free

AI Summary

AI-generated company analysis is available for registered users.

Sign up for free

Where does this data come from?

Frequently Asked Questions

What is Eli Lilly & Co.?
Eli Lilly and Company, commonly known as Lilly, is a global pharmaceutical company with a rich history of more than 140 years. Founded by Colonel Eli Lilly in 1876, the company has become a leader in the healthcare industry, dedicating its efforts and resources to develop innovative treatments to improve the lives of patients around the world. Lilly's focus on neuroscience underscores its commitment to finding solutions for some of the most complex and challenging diseases affecting the brain and nervous system. Through extensive research, Lilly aims to uncover new therapies to address conditions such as Alzheimer's disease, Parkinson's disease, migraine, depression, and schizophrenia. The company recognizes the immense burden that mental health disorders place on both patients and their families, and thus strives to provide effective treatment options that can enhance cognitive function, alleviate symptoms, and ultimately improve overall quality of life. In the realm of cardiometabolic disorders, Lilly has developed groundbreaking medications to treat conditions such as diabetes and cardiovascular diseases. One of their notable products, Jardiance, has been shown to dramatically reduce the risk of cardiovascular death in patients with type 2 diabetes mellitus. Additionally, Trulicity, a once-weekly injectable medication, has proven to be highly effective in managing blood sugar levels and reducing the risk of major adverse cardiovascular events. These medications exemplify Lilly's commitment to advancing treatments that not only address the symptoms but also target the underlying causes of cardiometabolic disorders. Lilly's dedication to oncology is evident through the development of Verzenio, a targeted therapy for breast cancer. Verzenio has shown promising results in extending survival and improving quality of life for patients battling advanced or metastatic breast cancer. The company is also involved in the exploration of other cancer treatments, with ongoing research and development efforts aimed at identifying innovative therapies for a wide range of malignancies. By collaborating with renowned oncology centers and experts worldwide, Lilly aims to contribute to significant advancements in cancer care. In the field of immunology, Lilly has made significant strides in developing medications for autoimmune diseases. Their product Taltz, for example, is used to treat conditions such as psoriasis, psoriatic arthritis, and ankylosing spondylitis. Taltz targets specific proteins involved in the body's immune response, effectively reducing inflammation and providing relief to patients suffering from these debilitating diseases. Another immunology product, Olumiant, has shown efficacy in the treatment of rheumatoid arthritis by inhibiting the activity of enzymes responsible for promoting inflammation within the joints. With a strong focus on research and development, Lilly continuously seeks to identify unmet medical needs and explore new therapeutic avenues. This commitment can be witnessed through their extensive clinical trials and collaborations with academic institutions, government agencies, and other pharmaceutical companies. By constantly pushing the boundaries of science and technology, Lilly aims to unlock potential breakthroughs in medicine that can revolutionize patient care and contribute to the advancement of global health. Overall, Eli Lilly's dedication to the areas of neuroscience, cardiometabolic disorders, oncology, and immunology demonstrates their steadfast commitment to improving the well-being of individuals worldwide. As a leading pharmaceutical company, Lilly strives to develop innovative treatments that address the most pressing medical challenges of our time. Through their cutting-edge research and collaborative efforts, they continue to make significant contributions to the field of healthcare, ultimately aiming to provide hope and restore health to patients in need.
Are Eli Lilly & Co. shares expensive?
The price-to-earnings (P/E) ratio of Eli Lilly & Co. is 38.46 — the share price is 38.46 times the annual profit per share. That is higher than the typical company in the same industry (industry median: 20.10). This is information, not a recommendation. (as of 2026-06-02)
How big is Eli Lilly & Co.?
The market capitalization of Eli Lilly & Co. — the combined value of all its shares — is 965.04 B USD. The higher the market cap, the larger the company. (as of 2026-06-02)
Does Eli Lilly & Co. pay dividends?
The dividend yield of Eli Lilly & Co. is 0.56% — it shows the annual dividend relative to the share price. This is information, not a recommendation. (as of 2026-06-02)
What sector does Eli Lilly & Co. belong to?
Eli Lilly & Co. operates in the Healthcare sector, industry: Drug Manufacturers - General.

What do you gain?

With Ecrumen you gain full control over your investments and assets!

All your assets
Stock market investments, real estate, bonds. Be aware of what you have in your portfolio!
AI at the service of your investments
Analyze and optimize your investments using the latest technologies. Sentiments, analyses, tips, reports. Always with up-to-date data!
A community eager to help
Find a place with people similar to you. Share your opinions, see how others manage their investments. Get help with the problems that bother you!
What do you gain?

Want to stay up to date?

Subscribe to our newsletter to stay up to date with Ecrumena news and market information. No spam, unsubscribe in one click.

For more information, please refer to our terms of use.

0/120